Search Result
Results for "
Lithocholic
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0172
-
-
-
- HY-B0172B
-
|
3β-Hydroxy-5β-cholanic acid; 3-EpiLithocholic acid; β-Lithocholic acid
|
Endogenous Metabolite
|
Endocrinology
|
|
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .
|
-
-
- HY-B0172A
-
|
3β-Hydroxy-5α-cholanic acid
|
Drug Derivative
|
Inflammation/Immunology
|
|
Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
|
-
-
- HY-143712
-
|
|
Drug Metabolite
G protein-coupled Bile Acid Receptor 1
ROR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .
|
-
-
- HY-B0172S
-
-
-
- HY-W587530
-
|
6-KetoLithocholic acid
|
Endogenous Metabolite
Apoptosis
|
Endocrinology
|
|
6-Oxolithocholic acid is a bile acid metabolite derived from Lithocholic acid (HY-B0172). 6-Oxolithocholic acid has high cytotoxicity and can induce apoptosis, especially in hepatocytes. 6-Oxolithocholic acid can participate in the regulation of bile acid metabolism and synthesis and affect the metabolic pathway of cholesterol. 6-Oxolithocholic acid can be used to study the role of bile acids in health and disease, especially in the context of digestive and liver diseases .
|
-
-
- HY-B0172R
-
|
3α-Hydroxy-5β-cholanic acid (Standard)
|
Reference Standards
Autophagy
Endogenous Metabolite
Apoptosis
FXR
|
Metabolic Disease
Cancer
|
|
Lithocholic acid (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .
|
-
-
- HY-113238A
-
|
SulfoLithocholic acid disodium; LCAS disodium
|
GPR39
ROR
|
Metabolic Disease
Inflammation/Immunology
|
|
Lithocholic acid 3-sulfate disodium is a GPR39 agonist, with EC50 values of 41 μM and 42.4 μM in M39-20 and hGPR39-2 cells, respectively, in the absence of Zn 2+, and 0.88 μM and 0.97 μM in the presence of Zn 2+. Lithocholic acid 3-sulfate disodium acts as a RORγt ligand. Lithocholic acid 3-sulfate disodium stimulates the GPR39 receptor to initiate intracellular calcium signaling, independent of the Zn 2+-binding sites H17 and H19. LCA-3-S selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate disodium can be used in the research of cholestatic liver diseases .
|
-
-
- HY-173496
-
|
|
Sialyltransferase
Integrin
VEGFR
Akt
|
Cancer
|
|
ST6GAL1-IN-1 is an orally active selective ST6GAL1 inhibitor (IC50 = 20 μM). ST6GAL1-IN-1 exhibits high antimetastatic potential, effectively inhibiting the migration of MDA-MB-231 cells at noncytotoxic concentrations. ST6GAL1-IN-1 can disrupt integrin sialylation in MDA-MB-231 cells. ST6GAL1-IN-1 inhibits tumor angiogenesis and cancer metastasis via the Integrin/VEGFR2-mediated signaling pathway. ST6GAL1-IN-1 effectively suppresses both tumor growth and cancer metastasis on the MDA-MB-231 xenograft model. ST6GAL1-IN-1 can be used for the study of Triple-negative breast cancer (TNBC) .
|
-
-
- HY-169393
-
-
-
- HY-177795
-
|
3,6-Diketo-LCA
|
Drug Derivative
|
Others
|
|
5β-Cholanic acid-3,6-dione (3,6-Diketo-LCA) is a similar substance to Lithocholic acid (LCA) (HY-B0172). 5β-Cholanic acid-3,6-dione cannot activate the Vitamin D receptor (VDR), and can be used as a negative control for studying the relationship between LCA derivatives and VDR .
|
-
-
- HY-118276
-
|
|
Drug Derivative
|
Cancer
|
|
Lithocholenic acid, a derivative of Lithocholic acid, possesses anti-tumor activity .
|
-
-
- HY-113238S1
-
-
-
- HY-B0172S1
-
-
-
- HY-113238F
-
|
FITC-SulfoLithocholic acid
|
Fluorescent Dye
|
Others
|
|
FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .
|
-
-
- HY-143712S1
-
|
3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4
|
Isotope-Labeled Compounds
Drug Metabolite
G protein-coupled Bile Acid Receptor 1
ROR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Allolithocholic Acid-d4 (3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .
|
-
-
- HY-113238AS
-
|
SulfoLithocholic acid-d4 disodium
|
Isotope-Labeled Compounds
|
Others
|
|
Lithocholic acid 3-sulfate-d4 (disodium) is the deuterium labeled Lithocholic acid 3-sulfate disodium .
|
-
-
- HY-B0172BR
-
|
3β-Hydroxy-5β-cholanic acid (Standard); 3-EpiLithocholic acid (Standard); β-Lithocholic acid (Standard)
|
Reference Standards
Endogenous Metabolite
|
Endocrinology
|
|
Isolithocholic acid (Standard) is the analytical standard of Isolithocholic acid. This product is intended for research and analytical applications. Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate[1][2].
|
-
-
- HY-B0172AR
-
|
3β-Hydroxy-5α-cholanic acid (Standard)
|
Drug Derivative
Reference Standards
|
Inflammation/Immunology
|
|
Isoallolithocholic acid (Standard) is the analytical standard of Isoallolithocholic acid. This product is intended for research and analytical applications. Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation[1].
|
-
-
- HY-169826
-
|
|
Biochemical Assay Reagents
|
Others
|
|
N-Lithocholyl-L-Leucine is a bile acid conjugate composed of Lithocholic acid (HY-B0172) and L-leucine (HY-N0486). N-Lithocholyl-L-Leucine can be used to form hydrogels .
|
-
-
- HY-B0172AS1
-
|
3β-Hydroxy-5α-cholanic acid-d4
|
Isotope-Labeled Compounds
Others
|
Inflammation/Immunology
|
|
Isoallolithocholic acid-d4 (3β-Hydroxy-5α-cholanic acid-d4) is deuterium labeled Isoallolithocholic acid. Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
|
-
-
- HY-N1780R
-
|
|
Reference Standards
Tyrosinase
Bacterial
|
Infection
|
|
3,4-Dimethoxyphenol (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. 3,4-Dimethoxyphenol is a plant-derived phenylpropanoid compound and can use as a whitening agent in cosmetics. 3,4-Dimethoxyphenol exhibits broad-spectrum antimicrobial activity. 3,4-Dimethoxyphenol has tyrosinase-inhibiting activity. 3,4-Dimethoxyphenol has potent antioxidant effect isolated from the bacterial fermentation broth. 3,4-Dimethoxyphenol can be used for the study of infection .
|
-
-
- HY-143712R
-
|
|
Reference Standards
Drug Metabolite
G protein-coupled Bile Acid Receptor 1
ROR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Allolithocholic acid (Standard) is the analytical standard of Allolithocholic acid (HY-143712). This product is intended for research and analytical applications. Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .
|
-
-
- HY-178721
-
|
|
Drug Derivative
Ephrin Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
|
|
Lithocholic amide-C2-N(didecane) (Compound LC10) is a Lithocholic acid (HY-B0172) analogue. Lithocholic amide-C2-N(didecane) can form lipid nanoparticles spontaneously in the aqueous milieu, permeate through the skin, penetrate the deeper dermal layers, and exert anti-inflammatory effects against psoriasis-like chronic skin inflammations. Lithocholic amide-C2-N(didecane) can inhibit abnormal proliferation of keratinocytes, downregulate the mRNA expression of the psoriasis-associated receptor EphA2 and reduce serum levels of multiple pro-inflammatory factors such as IL-1α, IL-1β, and IFN-γ by inhibiting activation of the Th17/Th2 inflammatory pathway .
|
-
-
- HY-N15432
-
|
|
Endogenous Metabolite
|
Others
|
|
4-Cholenic acid-3-one is an antifeedant steroid metabolite formed via anaerobic biotransformation of Lithocholic acid (HY-B0172) by Pseudomonas sp. strain NCIB 10590 .
|
-
-
- HY-181102
-
|
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
Inflammation/Immunology
|
|
TGR5 agonist 10 is a selective, allosteric and orally active Takeda G protein coupled receptor 5 (TGR5) agonist with EC50s of 0.8 μM and 0.6 μM for human TGR5 and mouse TGR5, respectively. TGR5 agonist 10 demonstrates selectivity for TGR5 over FXR. TGR5 agonist 10 activates hTGR5 and mTGR5 to induce cAMP accumulation, and positively modulates lithocholic acid functional activity and potency at hTGR5, with higher selectivity for cAMP formation over β-arrestin2 recruitment. TGR5 agonist 10 exerts glucose-lowering effects in Mus musculus oral glucose tolerance tests. TGR5 agonist 10 can be used for the research of diabetes .
|
-
-
- HY-P11614
-
|
|
Liposome
|
Cancer
|
|
LCA-H10 is a lithocholic acid-histidine decapeptide conjugate, a biocompatible lipid nanoparticle (LNP) additive that reduces ionizable lipid proportions, functions as an endosomal escape inducer, and enhances siRNA encapsulation. LCA-H10 increases hepatic accumulation of LNPs in mice after intravenous injection when incorporated into LiLNP-LH and reduces proinflammatory cytokines (IL-6, TNF, IL-1β) in mouse serum. LCA-H10 can be used for the research of prostate cancer .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-113238F
-
|
FITC-SulfoLithocholic acid
|
Fluorescent Dyes
|
|
FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .
|
| Cat. No. |
Product Name |
Type |
-
- HY-113238A
-
|
SulfoLithocholic acid disodium; LCAS disodium
|
Biochemical Assay Reagents
|
|
Lithocholic acid 3-sulfate disodium is a GPR39 agonist, with EC50 values of 41 μM and 42.4 μM in M39-20 and hGPR39-2 cells, respectively, in the absence of Zn 2+, and 0.88 μM and 0.97 μM in the presence of Zn 2+. Lithocholic acid 3-sulfate disodium acts as a RORγt ligand. Lithocholic acid 3-sulfate disodium stimulates the GPR39 receptor to initiate intracellular calcium signaling, independent of the Zn 2+-binding sites H17 and H19. LCA-3-S selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate disodium can be used in the research of cholestatic liver diseases .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P11614
-
|
|
Liposome
|
Cancer
|
|
LCA-H10 is a lithocholic acid-histidine decapeptide conjugate, a biocompatible lipid nanoparticle (LNP) additive that reduces ionizable lipid proportions, functions as an endosomal escape inducer, and enhances siRNA encapsulation. LCA-H10 increases hepatic accumulation of LNPs in mice after intravenous injection when incorporated into LiLNP-LH and reduces proinflammatory cytokines (IL-6, TNF, IL-1β) in mouse serum. LCA-H10 can be used for the research of prostate cancer .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0172
-
-
-
- HY-B0172B
-
-
-
- HY-143712
-
|
|
Structural Classification
Classification of Application Fields
Metabolic Disease
Endogenous metabolite
Disease Research Fields
Steroids
Source Classification
|
Drug Metabolite
G protein-coupled Bile Acid Receptor 1
ROR
|
|
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .
|
-
-
- HY-B0172R
-
-
-
- HY-B0172BR
-
-
-
- HY-N1780R
-
|
|
Structural Classification
Monophenols
Microorganisms
Phenols
Source Classification
|
Reference Standards
Tyrosinase
Bacterial
|
|
3,4-Dimethoxyphenol (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. 3,4-Dimethoxyphenol is a plant-derived phenylpropanoid compound and can use as a whitening agent in cosmetics. 3,4-Dimethoxyphenol exhibits broad-spectrum antimicrobial activity. 3,4-Dimethoxyphenol has tyrosinase-inhibiting activity. 3,4-Dimethoxyphenol has potent antioxidant effect isolated from the bacterial fermentation broth. 3,4-Dimethoxyphenol can be used for the study of infection .
|
-
-
- HY-143712R
-
|
|
Structural Classification
Endogenous metabolite
Steroids
Source Classification
|
Reference Standards
Drug Metabolite
G protein-coupled Bile Acid Receptor 1
ROR
|
|
Allolithocholic acid (Standard) is the analytical standard of Allolithocholic acid (HY-143712). This product is intended for research and analytical applications. Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .
|
-
-
- HY-N15432
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0172S
-
1 Publications Verification
|
|
Lithocholic acid-d4 is the deuterium labeled Lithocholic acid, which is a toxic secondary bile acid .
|
-
-
- HY-113238S1
-
|
|
|
Lithocholic acid 3-sulfate-d4（sodium salt） is the deuterium labeled Lithocholic acid 3-sulfate .
|
-
-
- HY-B0172S1
-
|
|
|
Lithocholic acid-d5 is deuterium labeled Lithocholic acid.
|
-
-
- HY-143712S1
-
|
|
|
Allolithocholic Acid-d4 (3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .
|
-
-
- HY-113238AS
-
|
|
|
Lithocholic acid 3-sulfate-d4 (disodium) is the deuterium labeled Lithocholic acid 3-sulfate disodium .
|
-
-
- HY-B0172AS1
-
|
|
|
Isoallolithocholic acid-d4 (3β-Hydroxy-5α-cholanic acid-d4) is deuterium labeled Isoallolithocholic acid. Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-B0172B
-
|
3β-Hydroxy-5β-cholanic acid; 3-EpiLithocholic acid; β-Lithocholic acid
|
|
Cholesterol
|
|
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .
|
-
- HY-169393
-
|
|
|
Cholesterol
|
|
N-Butyl lithocholic acid is a derivative of the secondary bile acid Lithocholic acid (HY-B0172) .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
